Confirmed Speakers
Professor Elijah R Behr
Director of the Cardiovascular and Genomics Research Institute
City St. George's, University of London
Professor Elijah Behr is an international expert in arrhythmias and Professor of Cardiovascular Medicine at St. Georges, University of London. He is a Consultant at St. George's NHS Foundation Trust and Mayo Clinic Healthcare, specializing in arrhythmias and genetic risks for sudden death. Behr has co-authored international guidelines and is a past president of the Association for Inherited Cardiac Conditions.
He chairs the Predisposition and Screening Genome England Clinical Interpretation Partnership and advises NHS England on cardiovascular and genomics services. His research on genomics, arrhythmias, and sudden death has led to over 300 publications.
Dr. David Harley
Strategic Director
Population Health Europe - Olink
David is Strategic Director of Population Health for Europe at Olink, leading the integration of proteogenomics to advance disease research. With a background in iPSC-based genetic studies and experience at Affymetrix and Thermo Fisher, he now helps bridge proteomics and genomics to improve understanding of disease mechanisms and enable targeted therapies. David is passionate about driving data-driven research to transform healthcare and public health outcomes.
Dr. Zoë Walters
Associate Professor in Translational Epigenomics
University of Southampton
Dr. Zoë Walters is an Associate Professor in Translational Epigenomics at the University of Southampton and co-leads the Innovation for Translation Research Group (ITRG) with Prof Tim Underwood. Her research focuses on the tumour microenvironment across cancers with high unmet need, including paediatric cancers, sarcomas, and oesophageal adenocarcinomas. The ITRG applies a precision medicine approach to explore therapy resistance, validate targets, develop pre-clinical models, and identify new biomarkers and treatments.
Dr. Stephanie Rossnagl
Senior Territory Account Manager
Illumina
Stephanie has over 10 years’ experience in genomics, spanning academic research and commercial roles. With a PhD in cancer biology, she has both practical and theoretical expertise in next-generation sequencing technologies and now partners with Illumina customers to enable scientific discovery across a range of applications, including genomics and other multiomic approaches.
Liz Welch
Senior Territory Account Manager
PacBio
Liz Welch is the Senior Account Manager for PacBio in the South of the UK, specializing in long-read sequencing technologies. She provides insights into the latest advancements in PacBio sequencing and their applications in research and clinical settings. Prior to joining PacBio, Liz led the UK Synthetic Biology sales team at Twist Bioscience, supporting researchers in molecular and synthetic biology.
Professor Dean Fennell
Professor & Consultant in Thoracic Medical Oncology & Director of Mesothelioma Research Programme
University of Leicester & University Hospitals of Leicester NHS Trust
Professor Dean Fennell is a physician scientistfocused on advancing stratified therapy and immuno-oncology for patients with mesothelioma. He has designed and led several investigator-initiated trials from phase 1 through phase III. His lab currently focuses on novel precision medicine strategies and understanding mesothelioma evolution.
He was past president of the International mesothelioma interest group (IMIG), past NCRI mesothelioma chair. He co-authored both the UK BTS, and European (ESMO, ERS) mesothelioma treatment guidelines, and served two terms on the EORTC board.
Mo Langhi
Vice President of Microbiome Software
Cmbio
Mo Langhi currently serves as Vice President of Microbiome Software at Cmbio where he’s responsible for the commercial growth and strategy for the Cosmos-Hub software; a user-friendly, no-code microbiome analysis platform for biologistics to conduct end-to-end microbiome and clinical metagenomics analysis. As a result of Mo’s 10+ years of commercial experience and 8+ years working in the microbiome field, he is well versed in microbiome science, associated lab processes and bioinformatics.
Novogene (UK) Company Limited, 25 Cambridge Science Park, Milton Road, Cambridge, CB4 0FW, United Kingdom
